Su X, et al. - Researchers determined how major clinical outcomes of adults with chronic kidney disease (CKD) are influenced by antiplatelet therapy, by analyzing randomized controlled trials that included adults with CKD and compared antiplatelet agents with controls. These studies were published before April 2019 and identified from MEDLINE, Embase, and the Cochrane Library for trials, via a systematic exploration. They identified 50 eligible trials, including at least one event. Overall, data were offered for 27,773 patients with CKD, including 4,518 major cardiovascular events and 1,962 all-cause deaths. A 15% attenuation in the odds of major cardiovascular events, a 48% decline for access failure events, was noted in relation to the use of antiplatelet therapy, which, however, significantly increased adverse events including major or minor bleeding. An overall net benefit of antiplatelet agents appeared among the participants because the antiplatelet therapy-conferred major prevention (cardiovascular events and access failure) might outweigh the risk of bleeding. The need for individual assessment and careful monitoring was also highlighted.